Hundreds hospitalized, more than 12 viruses circulating in CT. State saw 23 recent covid deaths.

Connecticut is experiencing a sharp rise in respiratory illnesses—particularly influenza—with roughly 5,000 confirmed flu cases at the end of December, 432 flu hospitalizations, about 18,000 total flu cases this season and over 7,000 COVID cases; the state recorded 9 COVID deaths in the week ending Dec. 20 and 23 in December. The CDC rates Connecticut's disease activity as very high, Farmington Valley reported a 79% one-week flu increase, and 18.6% of December emergency-department visits were flu-related. Public-health officials stress vaccine-preventable hospitalizations (influenza, RSV, COVID) and report 1.2 million residents received flu shots while 364,576 are recorded as having received a COVID vaccine after federal guidance changes; state action preserved insurance coverage for the COVID vaccine.

Analysis

Market structure: Rapid influenza + RSV + COVID mix favors makers of rapid diagnostics (Abbott ABT, Quidel QDEL), antivirals/flu vaccines (Roche RHHBY, Pfizer PFE, Moderna MRNA) and telehealth (Teladoc TDOC) for acute triage; hospitality, cruise/air (RCL, LUV) and restaurants see near-term demand compression. Diagnostics enjoy near-term pricing/volume power (weeks) as testing surges; vaccine makers get durable revenue optionality if booster campaigns restart but face margin press vs. generic antivirals. Supply-demand: expect 2–6 week testing lead-times and potential shortfalls in rapid-test kits; antiviral inventories can be ramped in 4–12 weeks, limiting sustained shortages but creating transient price/distribution advantages.

Risk assessment: Tail risks include a more virulent influenza strain driving hospitalization spikes (CT hospitalizations from 432 to >1,000/week would force statewide measures), federal policy shifts that reduce vaccine coverage (lowering PFE/MRNA uptake), or supply-chain disruptions for reagents. Immediate (days): surge in testing volumes and worker absenteeism; short-term (weeks–months): vaccine/antiviral order flows and Q1 earnings for diagnostics; long-term (quarters): potential normalization or policy-driven booster programs. Hidden dependencies: state/federal coverage decisions, wastewater viral indices, and school closure policies are key second-order drivers. Catalysts: CDC/wastewater readings crossing “high” or ED influenza% >20% will accelerate spending and price moves.

Trade implications: Tactical: establish a 2–3% long position in QDEL (or ABT) via short-dated (30–90 day) call spreads to capture winter testing demand; add 2% long PFE for RSV/flu vaccine exposure with 6–12 month horizon. Pair trade: long QDEL (2%) / short RCL (1–2%) to express diagnostics vs. leisure demand divergence. Options: buy Feb/Mar call spreads on QDEL sized to 1–2% NAV and use 5–7% OTM protection (puts) on RCL sized 0.5–1% as hedge. Entry window: act within 5–10 trading days; exit when CT ED influenza share drops below 10% or CDC wastewater viral load declines >50% from peak.

Contrarian angles: The market may be overpricing a multi-quarter tailwind for diagnostics — historical parallels (2017–18 severe flu) show 6–12 week peaks then normalization, creating risk of a post-spike inventory glut and margin compression. Consensus underestimates policy risk: a federal decision to limit boosters or restrict coverage can knock down vaccine demand by >30%. Unintended consequence: aggressive buying of test inventories now could trigger steep markdowns into Q2; size positions small, prefer time-limited options and clear exit triggers.

Key Decisions for Investors

• Establish a 2–3% NAV long in Quidel (QDEL) or Abbott (ABT) via 30–90 day call spreads to capture winter testing demand; size to 2% if ABT (broader business) or 3% if QDEL (pure-play rapid tests).
• Add a 1–2% NAV long in Pfizer (PFE) for RSV/flu vaccine exposure with a 6–12 month horizon; take profits if policy guidance reduces vaccine coverage by >20% or if CDC wastewater viral load falls >50% from current peak.
• Enter a pair trade: long QDEL (2%) / short Royal Caribbean (RCL) (1–2%) to isolate diagnostics upside vs. leisure-demand downside; close the short if RCL outperforms by >15% or QDEL underperforms by >10%.
• Use options: buy Feb/Mar call spreads on QDEL (1–2% NAV) and purchase 0.5–1% NAV puts on RCL as downside protection; exit options positions if CT ED influenza share <10% or within 60 days of trade initiation.
• Reduce discretionary/leisure exposure by 1–3% (e.g., XLY overweight downshift) and reallocate to healthcare diagnostics/pharma until winter surge subsides (target reassessment at 8–12 weeks or when ED influenza% drops below 12%).